

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62247 A1

(51) International Patent Classification⁷: **A61K 31/415, 31/42, 31/425**

(74) Agent: **RUGGIERO, Charles, N., J.; Ohlandt, Greeley, Ruggiero & Perle, L.L.P., One Landmark Square, 10th Floor, Stamford, CT 06901-2682 (US).**

(21) International Application Number: **PCT/US01/04304**

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(22) International Filing Date: **12 February 2001 (12.02.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/184,925 25 February 2000 (25.02.2000) US

(71) Applicant (for all designated States except US): **AVON PRODUCTS, INC. [US/US]; 1251 Avenue of the Americas, New York, NY 10020-1196 (US).**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

(72) Inventors; and

Published:

(75) Inventors/Applicants (for US only): **DUFFY, John, A. [US/US]; 47-F Manchester Lane, West Milford, NJ 07480 (US). PTCHELINTSEV, Dmitri, S. [RU/US]; 668 Juniper Way, Mahwah, NJ 07430 (US).**

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/62247 A1

(54) Title: **TOPICAL COMPOSITIONS CONTAINING THIAZOLIUM COMPOUNDS AND METHODS OF USING SAME**

(57) Abstract: It has been surprisingly discovered that thiazolium compounds may be used to topically treat telangiectasia or spider veins. It is believed that the thiazolium compounds act to restore the elasticity, and the healthy size and shape, of the affected arterioles. Accordingly, there is provided a topical composition having thiazolium compounds for skin care, dermatological applications, and the treatment of spider veins. In addition, this invention provides a method of treating spider veins by topically applying a composition having thiazolium compounds.

TOPICAL COMPOSITIONS CONTAINING THIAZOLIUM COMPOUNDS
AND METHODS OF USING SAME

Background of the Invention

5 1. Field of the Invention

The present invention relates to cosmetic and dermatological compositions. More particularly, the present invention relates to cosmetic and dermatological compositions containing thiazolium compounds.

10 2. Description of the Prior Art

Telangiectasia is a condition characterized by the dilation of one or more superficial arterioles in the human body, such that the effected arterioles become visible through the skin. In some cases, telangiectasia is symptomatic of a more serious disorder. However, telangiectasia occurs in

15 approximately 15% of the population as a purely cosmetic problem.

Telangiectasia is aesthetically objectionable and often becomes an increasingly common occurrence as an affected person ages. The objectionable nature of telangiectasia is evidenced by the common name for the disorder, i.e., "spider veins."

20

Spider veins are readily recognizable because of the characteristic shape and angry, red color of the dilated arterioles. In addition, spider veins typically blanch if pressure is applied to the nearby skin.

25

There are several techniques presently used to treat spider veins. First, several techniques for the treatment of spider veins involve invasive procedures that are intended to disrupt or destroy the arteriole. For example, hypertonic saline or octadocanol may be injected into a larger artery adjacent to the affected arterioles, which scleroses the larger artery

30

and effective "dries up" the spider veins. However, such invasive techniques are clearly undesirable because they require delicate operations that must be performed under the supervision of a physician.

Alternative techniques use laser light focused on the affected arterioles.

Furthermore, pigmented creams can be used to mask the spider veins.

More recently, topically applied compositions have been introduced
5 to treat spider veins. For example, U.S. Patent No. 5,268,176 discloses the
use of inositol phosphoric acid and its derivative in the treatment of spider
veins. Topical compositions are intended to treat the affected arterioles
and have several advantages, such as being non-invasive, simple, and
readily available. However, topical compositions are often less than totally
10 effective.

In light of the foregoing, there is an on-going need for a topically
applied compositions useful for treating dermatological conditions and,
especially, spider veins.

15

Summary of the Invention

It is an object of the present invention to provide a topical or
dermatological composition.

20 It is also an object of the present invention to provide a topical or
dermatological composition useful for the treatment of telangiectasia or
spider veins.

25 It is a further object of the present invention to provide such a
composition useful for the treatment of telangiectasia or spider veins, which
contains thiazolium, oxazolium, or imidozolium compounds.

It is yet another object of the present invention to provide a method
of treating telangiectasia or spider veins.

30

It has been surprisingly discovered that thiazolium, oxazolium, and
imidozolium compounds may be used to topically treat telangiectasia or
spider veins. It is believed that thiazolium, oxazolium, and imidozolium

compounds act to restore the elasticity, and the healthy size and shape, of the affected arterioles.

Accordingly, there is provided a topical composition having
 5 thiazolium, oxazolium, or imidozolium compounds for skin care, dermatological applications, and the treatment of spider veins. In addition, the present invention provides a method of treating spider veins by topically applying a composition having thiazolium, oxazolium, or imidozolium compounds.

10

Detailed Description of the Invention


As used herein, "alkyl" means a straight, branched, or cyclic hydrocarbon chain, saturated or unsaturated, and unsubstituted or substituted. "Aryl" means a moiety having an unsubstituted or substituted 15 aromatic ring. "Cyclic" means a moiety having an unsubstituted or substituted non-aromatic ring. "Anion" and "anionic" are interchangeable and refer to any ion or compound having a negative charge.

In accordance with the present invention, compositions and methods
 20 have been developed that are believed to treat superficial arterioles affected by telangiectasia. Specifically, it has been surprisingly discovered that the active compounds described herein may be used to topically treat spider veins. It is believed that the active compounds restore the elasticity, and the healthy size and shape, of the affected arterioles.

25

The topical compositions of the present invention have one or more active compounds described by the following general structure:

30



wherein:

Z is selected from the group consisting of sulfur, oxygen, and nitrogen;

R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, 5 benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic (saturated or unsaturated), and hydroxyalkyl groups. R₁ through R₄ may represent one or more ring structures, either independently or in combination; and

X is an anion or anionic compound.

10 When Z is oxygen, sulfur, or nitrogen, the above formula yields oxazolium, thiazolium, or imidazolium compounds, respectively.

A composition according to the present invention may contain one or more of the above described active compounds in any amount up to about 15 90% of the total weight of the composition (wt.%), preferably up to about 50 wt.%, and, more preferably, up to about 20 wt.% in a physiologically acceptable vehicle.

20 The active compounds used in the compositions of the present invention may be prepared according to any method. For example, thiazolium compounds for use in the present invention may be prepared according to the procedures described in U.S. Patent No. 5,656,261, which is incorporated herein by reference.

25 According to the present invention, the active compounds are topically applied in a carrier. As used herein, a carrier is a formulation within which a particular active compound, such as a thiazolium compound, is applied to the skin. The carrier may be a physiologically acceptable carrier that does not produce significant irritation upon contact with human 30 skin. A carrier for use in the present invention can be of any form, such as a solid, a fluid, an emulsion or an aerosol. Examples of a solid carrier include patches, tapes, powders, and other dry solid carrier obvious to

those skilled in the art. Examples of a fluid carrier include creams, lotions, gels, and any other fluid carrier obvious to those skilled in the art.

In addition to above described active compounds, the compositions 5 of the present invention may also contain one or more additional compounds. For example and without limitation, a composition according to the present invention may contain one or more emollients (preferably in an amount up to about 30 wt.%), one or more emulsifiers (preferably in an amount up to about 20 wt.%), one or more preservatives (preferably in an 10 amount up to about 5 wt.%), one or more alcohols (preferably in an amount up to about 95 wt.%), one or more fragrances (preferably in an amount up to about 5 wt.%), one or more thickening agents (preferably in an amount up to about 10 wt.%), one or more humectants (preferably in an amount up to about 25 wt.%), one or more colorants (preferably in an amount up to 15 about 1 wt.%), one or more silicones (preferably in an amount up to about 50 wt.%), one or more exfoliating agents (preferably in an amount up to about 70 wt.%), one or more keratolytic agents (preferably in an amount up to about 50 wt.%), one or more retinoids (preferably in an amount up to about 10 wt.%), one or more sunscreens, such as avobenzene, octyl 20 salicylate, octyl methoxycinnamate, and octocrylene (preferably in an amount up to about 30 wt.%), one or more skin penetration enhancers (preferably in an amount up to about 25 wt.%), one or more anti- inflammatory agents (preferably in an amount up to about 50 wt.%), one or more vitamins (preferably in an amount up to about 50 wt.%), one or more 25 thrombolytic agents (preferably in an amount up to about 50 wt.%), one or more anticoagulants (preferably in an amount up to about 30 wt.%), one or more capillary protectants (preferably in an amount up to about 70 wt.%), and one or more antioxidants (preferably in an amount up to about 80 wt.%).

30

Furthermore, other compounds that may be incorporated into the composition include: one or more hormones (preferably in an amount up to about 5 wt.%), one or more antibacterial agents (preferably in an amount up to

about 20 wt.%), one or more analgesics (preferably in an amount up to about 50 wt.%), one or more lipophilic compounds (preferably in an amount up to about 90 wt.%), one or more antihistamine agents (preferably in an amount up to about 20 wt.%), one or more insect repellants (preferably in an amount up to about 90 wt.%), one or more skin cooling compounds (preferably in an amount up to about 90 wt.%), one or more lubricants (preferably in an amount up to about 50 wt.%), one or more anti-fungal agents (preferably in an amount up to about 50 wt.%), one or more skin-whitening agents (preferably in an amount up to about 50 wt.%), and mixtures thereof.

5 to about 90 wt.%), one or more skin cooling compounds (preferably in an amount up to about 90 wt.%), one or more lubricants (preferably in an amount up to about 90 wt.%), one or more anti-fungal agents (preferably in an amount up to about 50 wt.%), one or more skin-whitening agents (preferably in an amount up to about 50 wt.%), and mixtures thereof.

10

The following are examples of compositions according to the present invention.

Example 1: Oil-In-Water Emulsion Composition

	<u>Ingredient</u>	<u>wt.%</u>
15	3-(2-methyl-2-oxoethyl)-thiazolium chloride	1.00
	Glyceryl stearate	8.00
	Cetearyl alcohol	1.50
	Cetearyl Octanoate	1.50
20	Octylpalmitate	4.00
	Butylene Glycol	5.00
	Glycerine	4.00
	Methyl Paraben	0.40
	Fragrance	0.01
25	Water	qs

Example 2: Cream Composition

	<u>Ingredient</u>	<u>wt.%</u>
	Cetyl alcohol	2.00
30	Glyceryl monostearate	2.50
	3-propargyl-4-methyl-thiazolium bromide	0.50
	White Petrolatum	5.00
	3,4-dimethyl-5-(2-hydroxyethyl)-thiazolium iodide	5.00

Octyl Palmitate	8.00
Steareth-2	1.00
Peg-40 Stearate	2.00
Triethanolamine	to pH=6.00
5 Water	qs

Example 3: Lotion Composition

<u>Ingredient</u>	<u>wt.%</u>
Xanthan Gum	0.25
10 Hydroxyethyl cellulose	0.35
3-ethyl-5-(2-hydroxyethyl)-4-methylthiazolium chloride	2.00
Propylene glycol	5.00
Tocopherol	0.10
Caprylic/Capric triglyceride	9.00
15 Steareth 2	1.50
Lactic acid	2.00
Ammonium hydroxide	to pH 3.8
Water	qs

20

Example 4: Toner

<u>Ingredient</u>	<u>wt.%</u>
Ethyl alcohol	40.00
2-(2-phenyl-2-oxoethyl)-4-methylthiaxolium bromide	10.00
Glycerine	5.00
25 Disodium EDTA	0.25
Lactic acid	1.00
Salicylic acid	1.50
Ammonium hydroxide	to pH 4.0
Water	qs

30

Example 5: Ointment

<u>Ingredient</u>	<u>wt.%</u>
Petrolatum	68.99

Shae butter	10.00
Lipophilic rosemary extract	0.01
Apigenin	1.00
3-(2-methoxy-2-oxoethyl) benzothiazolium chloride	20.00

5

Example 6: Anhydrous Tonic

<u>Ingredient</u>	<u>wt.%</u>
Silicone oil	30.00
Propylene glycol	2.00
10 Phenethyl isothiocyanate	0.01
3-(2-phenyl-2-oxoethyl)thiazolium chloride	0.5
Fragrance	0.15
Colorant	0.01
Anhydrous ethanol	qs

15

Example 7: Silicone Emulsion

<u>Ingredient</u>	<u>wt.%</u>
Cyclomethicone/Dimethicone copolyol	10.00
Cyclomethicone pentamer	15.00
20 Sodium Chloride	0.50
Glycerine	5.00
Preservative	0.15
Decylisothiocyanate	1.00
3-(2-phenyl-2-oxoethyl)-4-methylthiazolium chloride	5.00
25 water	qs

In use, a composition according to the present invention may be applied topically in any amount and according to any schedule. Use of the composition is limited only by the particular circumstances of use, which 30 may include treatment of, for example, skin pigmentation, age spots, wrinkles, lack of elasticity of the skin, poor skin texture, poor skin tone, and poor skin clarity. The particular circumstances of use may also include one or more of the aesthetic goals, such as, reducing dermatological aging


(particularly dermatological aging due to hormonal aging), decreasing skin fragility, preventing and reversing loss of collagen, preventing skin atrophy, promoting/accelerating cell turnover, improving skin firmness/plumpness, improving skin texture, decreasing fine lines and wrinkles, improving skin 5 tone, enhancing skin thickness, decreasing pore size, minimizing skin discoloration, restoring skin luster, minimizing signs of fatigue, reducing acne, and improving skin clarity.

The present invention having been described with particular 10 reference to the preferred forms thereof, it will be obvious that various changes and modifications may be made herein without departing from the spirit and scope of the invention as defined in the appended claims.

Wherefore w_ claim:

1. A method for the treatment of telangiectasia comprising the step of topically applying to said telangiectasia a composition including one or more active compounds described by the following general structure:

5



wherein:


10 Z is selected from the group consisting of sulfur, oxygen, and nitrogen;

R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thiienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R₁ through R₄ may represent one or more ring structures, either independently or in combination; and

X is anionic.

2. A method for the treatment of the skin comprising the step of 20 topically applying to said skin a composition including one or more active compounds described by the following general structure:

25



wherein:


Z is selected from the group consisting of sulfur, oxygen, and nitrogen;

R₁, R₂, R₃, and R₄ are independently selected from the group 30 consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thiienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R₁ through R₄ may represent one or more ring structures, either independently or in combination; and

X is anionic.

3. The method of claim 2, wherein said treatment is for one or more of the conditions selected from the group consisting of: skin 5 pigmentation, age spots, wrinkles, lack of elasticity of the skin, poor skin texture, poor skin tone, poor skin clarity.

4. A method for improving the aesthetic appearance of the skin comprising the step of topically applying to said skin a composition 10 including one or more active compounds described by the following general structure:



wherein:

Z is selected from the group consisting of sulfur, oxygen, and nitrogen;

20 R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thiienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R₁ through R₄ may represent one or more ring structures, either independently or in combination; and

X is anionic.

25

5. The method of claim 4, wherein the improvement in aesthetic appearance includes at least one of the following:


- a. Reducing dermatological aging, particularly dermatological aging due to hormonal aging;

30 b. Decreasing skin fragility;

- c. Preventing and reversing loss of collagen;
- d. Preventing skin atrophy;
- e. Promoting/accelerating cell turnover;

- f. Improving skin firmness/plumpness;
- g. Improving skin texture;
- h. Decreasing fine lines and wrinkles;
- i. Improving skin tone;
- 5 j. Enhancing skin thickness;
- k. Decreasing pore size;
- l. Minimizing skin discoloration;
- m. Restoring skin luster;
- n. Minimizing signs of fatigue;
- 10 o. Reducing acne; and
- p. Improving skin clarity.

6. A composition for topical application to telangiectasia, said composition comprising a physiologically acceptable carrier and one or 15 more active compounds described by the following general structure:



20 wherein:

Z is selected from the group consisting of sulfur, oxygen, and nitrogen;

25 R₁, R₂, R₃, and R₄ are independently selected from the group consisting of hydrogen, amino, alkyl, alkoxy, alkenyl, alkynyl, hydroxy, aryl, benzyl, phenethyl, thienyl, pyrrolyl, phenyl group, cyclic, and hydroxyalkyl groups. R₁ through R₄ may represent one or more ring structures, either independently or in combination; and

X is anionic.

30 7. The composition of claim 6, wherein said one or more active compounds are selected from the group consisting of: 3-(2-methyl-2-oxoethyl)-thiazolium chloride, 3-propargyl-4-methyl-thiazolium bromide, 3,4-dimethyl-5-(2-hydroxyethyl)-thiazolium iodide, 3-ethyl-5-(2-

hydroxyethyl)-4-methylthiazolium chloride, 2-(2-phenyl-2-oxoethyl)-4-methylthiazolium bromide, 3-(2-methoxy-2-oxoethyl) benzothiazolium chloride, 3-(2-phenyl-2-oxoethyl)thiazolium chloride, 3-(2-phenyl-2-oxoethyl)-4-methylthiazolium chloride, and mixtures thereof.

5

8. The composition of claim 6, wherein said physiologically acceptable carrier may be applied to skin without irritation and is selected from the group consisting of comprises a solid, a fluid, an emulsion, an aerosol, and mixtures thereof.

10

9. The composition of claim 8, wherein said physiologically acceptable carrier is selected from the group consisting of: patches, tapes, powders, a dry solid, creams, lotions, gels, and combinations thereof.

15

10. The composition of claim 6, further comprising one or more additional compounds selected from the group consisting of: emollients, emulsifiers, preservatives, alcohols, fragrances, thickening agents, humectants, colorants, silicones, exfoliating agents, keratolytic agents, retinoids, sunscreens, skin penetration enhancers, anti-inflammatory

20

agents other than thiazolium compounds, vitamins, thrombolytic agents, anticoagulants, anticoagulants, capillary protectants, antioxidants, hormones, antibacterial agents, analgesics, lipophilic compounds, antihistamine agents, insect repellants, skin cooling compounds, lubricants, anti-fungals, and mixtures thereof.

25

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/04304

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) :A61K 31/415, 31/42, 31/425
US CL :514/365, 374, 369

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/365, 374, 369

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS-ON-LINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,268,176 A (ZNAIDEN et al.) 07 December 1993, see the entire document.	1-10

<input type="checkbox"/>	Further documents are listed in the continuation of Box C.	<input type="checkbox"/>	See patent family annex.
	Special categories of cited documents:		
A	document defining the general state of the art which is not considered to be of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
B	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means	*Z*	document member of the same patent family
P	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 04 MAY 2001	Date of mailing of the international search report 25 MAY 2001
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer KEVIN E. WEDDINGTON Telephone No. (703) 308-1235 